Salute e Benessere

Healthcare Executives Embrace Generative AI to Boost Patient Outcomes

The article continued: At Fortune'srecent Brainstorm AI conference in San Francisco, several healthcare executives voiced their expectation that the technology will transform the field. According to analysts at MarketsandMarkets Research, the Global AI in Healthcare Market is set to hit US$164.16 billion by 2030, growing at an explosive 49.1% CAGR. The article continued: At Fortune'srecentBrainstorm AI conference inSan Francisco, several healthcare executives voiced their expectation...

Structural Heart Devices Market to Hit USD 25.69 Billion by 2029 with 9.5% CAGR…

Browse in-depth TOC on "Structural Heart Devices Market"359 - Tables53 - Figures304 - Pages Browse in-depth TOC on "Structural Heart Devices Market" 359 - Tables 53 - Figures 304 - Pages Based on product, the Structural heart devices market is segmented into Heart Valve Devices, Occluders, Closure systems and Delivery systems, Annuloplasty rings, and accessories. The Heart valve devices are further segmented into transcatheter heart valves and surgical heart valves...

AIM ImmunoTech Expands Patent Portfolio with New Netherlands Composition and…

AIM ImmunoTech Inc.(NYSE American: AIM) (“AIM” or the “Company”) today announced that the Netherlands Patent Office (Octrooicentrum Nederland) has granted Patent No. 2,032,813 — a compositions and methods patent — covering Ampligen ®(rintatolimod) for use in the treatment of the post-COVID condition of fatigue. The patent inventors, AIM CEO Thomas K. Equels and AIM Medical Officer David R. Strayer, M.D., have assigned the granted patent to the Company.AIM CEO Thomas K. Equels...

Coronado Research announce appointment of Dr. Jennifer Bradford as VP, Head of…

Coronado Research Chief Scientific Officer, Professor Jennifer Visser-Rogers said, "Jenny brings a wealth of experience in data science, and is expert in using AI and data science to help companies extract value from their data. She will support our vision of advancing pharmaceutical research through cutting-edge data-driven clinical trials that leverage emerging technologies to create a more effective and equitable model." Coronado Research Chief Scientific Officer…

iTeos Therapeutics Presents Interim A2A-005 Clinical Trial Data, Translational…

- Inupadenant + carboplatin/pemetrexed in Phase 2 A2A-005 trial demonstrated a 63.9% overall response rate (ORR) and a median PFS of 7.7 months for all evaluable patients across the cohorts - Recommended Phase 2 dose (RP2D) of inupadenant 80mg + carboplatin/pemetrexed demonstrated 73.3% ORR, with 64.6% of patients achieving landmark 6-month PFS - Inupadenant + carboplatin/pemetrexed safety profile was manageable and tolerable, with no dose-dependent toxicity observed - Inupadenant...

Novo Nordisk A/S: European regulatory authority adopts positive opinion for an…

Bagsværd, Denmark, 12 December 2024– Novo Nordisk today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for an update of the Ozempic ®(once-weekly subcutaneous semaglutide) label to reflect data from the FLOW kidney outcomes trial. The FLOW trial assessed the risk reduction from Ozempic ®therapy in chronic kidney disease-related events, including persistent ≥50% decline in estimated glomerular...

Zymeworks Hosts R&D Day Highlighting Continued Clinical Progress in Oncology…

Company on track to deliver five Investigational New Drug (IND) applications as part of '5 by 5' solid tumor strategy 18 months ahead of original targetNomination of ZW209, a novel trispecific T cell engager, as fifth development candidate in the Company's solid tumor portfolioExpansion into autoimmune and inflammatory diseases (AIID) and hematology oncology leverages the Company's clinically validated Azymetric™ technology platform and expertise in multispecific therapeutics ...

Evaxion establishes new AI-derived precision cancer vaccine concept

Evaxion's AI-Immunology™ platform allows for the design of precision cancer vaccines targeting non-conventional ERV tumor antigens shared across patientsNovel preclinical data confirms the effectiveness of the precision vaccine approach by inducing strong T-cell responses and tumor growth inhibition in mice, thereby establishing preclinical Proof-of-ConceptThe approach could allow for a broader use of cancer vaccines, also for patients not responding to conventional immunotherapies ...

Elevation Oncology Licenses ADC Technology from Synaffix to Drive Pipeline…

Under the terms of the agreement, Synaffix is eligible to receive up to USD 368 million in upfront and clinical, regulatory, and commercial milestone payments, plus tiered royalties on net sales. Synaffix is responsible for manufacturing the components related to its proprietary technologies, and Elevation Oncology is responsible for the research, development, manufacturing, and commercialization of the ADC. Under the terms of the agreement, Synaffix is eligible to receive up toUSD 368...

BC Platforms-Nottingham Partnership to Power World-Leading University and…

New contract with the University of Nottingham and Nottingham University Hospitals NHS Trust to boost data capabilities, sharing, and innovation – accelerating dialogue and data sharing between clinicians and basic researchers to ultimately benefit patients.Part of a larger programme seeking to learn insights from other healthcare systems that could benefit patients in Nottingham – ensuring data security while enabling the sharing of trends and results with significant global relevance...

Menarini Group and MEDSIR Present the Phase III Study ADELA: A New Therapeutic…

This combination is being evaluated in patients with advanced ER+/HER2- breast cancer that harbors ESR1 mutations, and who have experienced progression after standard first-line treatment. Results from the phase III EMERALD study were the basis for elacestrant's approval. Meanwhile, everolimus has shown efficacy in inhibiting other resistance mechanisms in this type of cancer. The elacestrant and everolimus combination has demonstrated preliminary efficacy with a manageable safety profile in…

COSRX Unveils The New Advanced Snail Mucin Glass Glow Hydrogel Mask

The Advanced Snail Mucin Glass Glow Hydrogel Mask is formulated with a high concentration of Snail Secretion Filtrate (Mucin) to deliver powerful all-in-one skincare benefits in a single use. Using innovative hydrogel technology, the mask gradually turns transparent as its active ingredients are absorbed into the skin, offering hydrating, brightening, soothing, and firming effects while improving overall skin texture and radiance. Uniquely, the mask can also be used overnight, making it ideal…

Neuraxpharm and Pharmathen enter into strategic co-development agreement to…

Under this agreement, Neuraxpharm will have exclusive rights to commercialise these therapies in Europe, and in countries outside of Europe where the group has a direct presence, while Pharmathen will have exclusive rights for North America and all other countries not covered by Neuraxpharm. Under this agreement, Neuraxpharm will have exclusive rights to commercialise these therapies inEurope, and in countries outside ofEuropewhere the group has a direct presence, while Pharmathen will...

General Inception acquires Enable Medicine and announces strategic partnership…

Power of generative biological search Power of generative biological search Enable Medicine harnesses the revolutionary capabilities of AI to guide novel insights into biology and medicine. The platform unlocks the power of generative biological search, which uses cutting-edge AI models to search maps of disease for novel drug targets and indications. The approach prioritizes indexing high quality multimodal cellular data to enable the research community and pharmaceutical industry to...

SpliceBio Announces U.S. FDA IND Clearance of SB-007 to Commence Phase 1/2…

"Stargardt disease has been a challenge for the development of gene therapies due to the large size of the ABCA4 gene, and currently has no approved therapies available," said Professor Paul Yang, M.D., Ph.D., Chief of the Paul H. Casey Ophthalmic Genetics Division at Casey Eye Institute at Oregon Health & Science University. "This new therapy utilizes a unique approach to replace the full-size, normal ABCA4 protein at high efficiency, which addresses the root cause of…

Breakthrough in Lupus Treatment: Isotopia Partners with LIVEKIDNEY.BIO

This partnership combines LIVEKIDNEY.BIO's pioneering work in lupus treatment with Isotopia's world-class manufacturing capabilities at our state-of-the-art aseptic plant. Our commitment to quality and safety ensures the highest standards in producing a key therapeutic agent for treating lupus. This partnership combines LIVEKIDNEY.BIO's pioneering work in lupus treatment with Isotopia's world-class manufacturing capabilities at our state-of-the-art aseptic plant. Our commitment to quality and...

DeerRun Set to Enter the German Market with Smart Treadmills, Offering…

Since its launch, DeerRun has quickly become a leading smart treadmill brand in North America, thanks to its innovative products and the PitPat platform, known as the "Online Olympics Platform." With over 1 million treadmills sold globally, DeerRun engages tens of thousands of users daily in virtual races and fitness challenges on PitPat. Since its launch, DeerRun has quickly become a leading smart treadmill brand inNorth America, thanks to its innovative products and…

A public organisation has chosen the Aino SaaS platform

Yet another public organization haschosenAino's SaaS platform. As part of a comprehensive strategy to be more socially sustainable, more productive and gain attraction as an employer, to manage staffing needs and secure the competence supply. Theagreementincludes a total of 600 employees and the Aino SaaS platform is in production-use from the first quarter of 2025. “All Ainos public customers work hard every day to find and to keep employees with the right competence, to...

Sectra's six-month interim report 2024/2025: Order bookings at a record high

Six-month period: May–October 2024 in figures Six-month period: May–October 2024 in figures Comments from Torbjörn Kronander, President and CEO of Sectra AB"The first half of the year can be summarized as follows: record-breaking order bookings, a continued positive trend for secure communications and significant progress in the transition to selling medical diagnostic imaging as a service. More extensive contracts with customers lead to large variations in order bookings, sales and...

HANZA acquires Leden - a billion SEK Finnish manufacturer

With this acquisition, HANZA is expanding its offering in Finland in particular, but also in the Baltics. Among other things, this means increased capacity and expertise in advanced mechanics manufacturing. With this acquisition, HANZA is expanding its offering inFinlandin particular, but also in the Baltics. Among other things, this means increased capacity and expertise in advanced mechanics manufacturing. Summary of the transaction Management comments "The acquisition of...

Essential Pharma announces €900 million recapitalisation through a Gyrus Capital…

Essential Pharma announces €900 million recapitalisation through a Gyrus Capital Continuation Vehicle led by AlpInvest and new strategic financing from Sixth StreetProvides significant resources to build on diversified portfolio of established and rare disease medicinesEgham, UK – 12 December 2024– Essential Pharma (“Essential” or “the Company”), an international specialty pharma group focused on ensuring that patients have access to low volume, clinically differentiated, niche...

ONWARD Medical Ranks in Top 15 Percent Globally for Corporate Sustainability

EcoVadis silver medal recognizes Company's environmental and social impactDemonstrates ongoing commitment to integrating sustainable business practices EINDHOVEN, the Netherlands, Dec.12, 2024(GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative spinal cord stimulation therapies to restore movement, function, and independence in people with spinal cord injury (SCI), today announces it has been awarded a silver medal by EcoVadis,...

Alma Expands Injectables Presence in APAC with Profhilo® Launch in Thailand

The flagship Swiss-based bio-remodeler, Profhilo®, delivers a unique "beneath-the-skin" hyaluronic acid treatment, powered by patented NAHYCO® technology. This advanced formulation provides a prolonged stimulating effect on dermal cells, rejuvenating the skin by improving laxity, skin quality and restoring firmness. The flagship Swiss-based bio-remodeler, Profhilo®, delivers a unique "beneath-the-skin" hyaluronic acid treatment, powered by patented NAHYCO® technology. This…

T-cell Malignancies Market Dynamics: Key Insights on Acute Lymphocytic Leukemia…

These malignancies are often more aggressive and harder to treat than B-cell cancers due to their complex biology and resistance to conventional therapies. Symptoms can vary but typically include enlarged lymph nodes, fever, night sweats, and weight loss. Treatment options include chemotherapy, radiation therapy, and novel therapies like CAR T-cell therapy and targeted therapies, which are advancing the understanding and management of these challenging cancers. These malignancies are often…

Altri Comunicati